Antidiabetic Plant Extracts
Volume 3 - Issue 1
Jagessar RC*
-
Author Information
Open or Close
- Department of Chemistry, University of Guyana, South America
*Corresponding author:
Jagessar RC, Department of Chemistry, University of Guyana, South America
Received: April 08, 2019; Published: April 15, 2019
DOI: 10.32474/DDIPIJ.2018.03.000152
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Diabetes mellitus is a chronic health problem with long term consequences that are potentially preventable. It is a heterogeneous
group of disease, characterized by high blood glucose levels resulting from impaired insulin secretion, impaired insulin action,
or both. There are several synthetic antidiabetic drugs. These include Insulin Secretagogues (Sulfonylureas), biguanides,
Thiazolidinediones, α- Glucosidase, Glucagon. Although, antidiabetic agents such as insulin, biguanides, thiazolidinediones and α
glucosidase inhibitors are available in Guyana to treat diabetes, a safe and effective treatment paradigm is yet to be achieved. This
is due to that fact that these drugs fail to significantly reduce the course of diabetic complications and have limited use because
of their undesirable pathological conditions and high secondary failure rates. Therefore, it is essential to discover more effective
antidiabetic agents with few adverse effects, low costs and ease of accessibility. In recent years, there has been a resurgence of
interest in medicinal plants for the treatment of diseases. A World Health Organization (WHO) study shows that 80% of the world’s
population solely relies on medicinal plants for their primary health care needs. Medicinal plant extracts, having antidiabetic
properties can be a useful source for the development of oral hypoglycemic agents in both animal models and human subjects. Over
350 plants are used in the treatment of diabetes mellitus, but only a small number of these plants had gained scientific and medical
evaluation to assess their effectiveness and efficacy.
Keywords:Diabetes; Chronic; Synthetic antidiabetic drugs; World Health Organisation; WHO
Abstract|
Introduction|
Conclusion|
Refernces|